Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018160909) GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/160909 International Application No.: PCT/US2018/020562
Publication Date: 07.09.2018 International Filing Date: 02.03.2018
IPC:
A61K 39/395 (2006.01) ,A61K 38/17 (2006.01) ,C07K 16/30 (2006.01) ,C07K 16/46 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17
from animals; from humans
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
30
from tumour cells
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
46
Hybrid immunoglobulins
Applicants:
SIAMAB THERAPEUTICS, INC. [US/US]; 90 Bridge Street Suite 100 Newton, Massachusetts 02458, US
Inventors:
DRANSFIELD, Daniel T.; US
PRENDERGAST, Jillian M.; US
EAVARONE, David A.; US
Agent:
WARD, Donna T.; US
SULLIVAN, Christopher P.; US
Priority Data:
62/466,76603.03.2017US
62/480,12631.03.2017US
62/486,82618.04.2017US
62/563,71827.09.2017US
62/577,83027.10.2017US
Title (EN) GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE
(FR) COMPOSÉS INTERAGISSANT AVEC LE GLYCANE ET MÉTHODES D'UTILISATION
Abstract:
(EN) Methods of treating cancer are provided that include administering glycan-interacting antibodies. Included are anti-sialyl Tn antigen antibodies and related compositions and formulations suitable to achieve desirable bioactivity, bioavailability, and toxicity levels.
(FR) L'invention concerne des méthodes de traitement du cancer qui consistent à administrer des anticorps interagissant avec le glycane. L'invention concerne également des anticorps anti-antigène sialyl Tn et des compositions et des formulations associées appropriées pour permettre d'obtenir une bioactivité, une biodisponibilité et des niveaux de toxicité souhaitables.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)